Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Systematic Review and Meta-Analysis: Is There a Benefit in Using Neoadjuvant Systemic Chemotherapy in Locally Advanced Penile Squamous Cell Carcinoma?

Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE.

J Urol. 2020 Jan 13:101097JU0000000000000746. doi: 10.1097/JU.0000000000000746. [Epub ahead of print]

PMID:
31928407
2.

Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?

Choo R, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ.

Minerva Urol Nefrol. 2019 Jul 25. doi: 10.23736/S0393-2249.19.03387-3. [Epub ahead of print]

PMID:
31353875
3.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML.

JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393.

PMID:
31021376
4.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
5.

Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.

Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC.

J Urol. 2018 Nov;200(5):1075-1081. doi: 10.1016/j.juro.2018.04.070. Epub 2018 Apr 27.

PMID:
29709664
6.

Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.

Bhindi B, Habermann EB, Mason RJ, Costello BA, Pagliaro LC, Thompson RH, Leibovich BC, Boorjian SA.

J Urol. 2018 Sep;200(3):528-534. doi: 10.1016/j.juro.2018.03.077. Epub 2018 Mar 21.

PMID:
29574109
7.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
8.

Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30238-0. doi: 10.1016/j.clgc.2017.07.028. [Epub ahead of print]

9.

Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy.

Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH, Tollefson MK, Boorjian SA, Pagliaro LC, Karnes RJ.

Clin Genitourin Cancer. 2017 Jul 22. pii: S1558-7673(17)30207-0. doi: 10.1016/j.clgc.2017.07.010. [Epub ahead of print]

PMID:
28818551
10.

New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis.

Aragon-Ching JB, Pagliaro LC.

Am Soc Clin Oncol Educ Book. 2017;37:330-336. doi: 10.14694/EDBK_175558. Review.

11.

Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.

Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

Eur Urol. 2017 Nov;72(5):660-664. doi: 10.1016/j.eururo.2017.05.016. Epub 2017 May 22.

PMID:
28545841
12.

Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.

Pagliaro LC.

J Clin Oncol. 2017 Apr 1;35(10):1036-1040. doi: 10.1200/JCO.2016.70.6523. Epub 2016 Dec 19. Review.

PMID:
27992270
13.

Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma.

Reddy JP, Pettaway CA, Levy LB, Pagliaro LC, Tamboli P, Rao P, Jayaratna I, Hoffman KE.

BJU Int. 2017 Apr;119(4):591-597. doi: 10.1111/bju.13686. Epub 2016 Nov 8.

14.

Multimodal Therapy in the Management of Advanced Penile Cancer.

Ravi P, Pagliaro LC.

Urol Clin North Am. 2016 Nov;43(4):469-479. doi: 10.1016/j.ucl.2016.06.008. Review.

PMID:
27717433
15.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C.

J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.

16.

Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.

Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL.

Cancer. 2016 Jun 15;122(12):1836-43. doi: 10.1002/cncr.29996. Epub 2016 Mar 28.

17.

Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.

Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC.

Urology. 2016 Mar;89:83-9. doi: 10.1016/j.urology.2015.12.007. Epub 2015 Dec 23.

18.

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):276-80. doi: 10.1038/pcan.2015.23. Epub 2015 May 26.

19.

Management of Clinical Stage I Testicular Cancer: How Should We Define Success?

Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ.

J Clin Oncol. 2015 Jul 10;33(20):2321-2. doi: 10.1200/JCO.2015.60.8885. Epub 2015 Jun 1. No abstract available.

PMID:
26033805
20.

Role of chemotherapy in treatment of squamous cell carcinoma of the penis.

Pagliaro LC.

Curr Probl Cancer. 2015 May-Jun;39(3):166-72. doi: 10.1016/j.currproblcancer.2015.03.008. Epub 2015 Mar 31. Review. No abstract available.

PMID:
25920379
21.

Reply: To PMID 25819619.

Wang J, Pettaway CA, Pagliaro LC.

Urology. 2015 May;85(5):1110. doi: 10.1016/j.urology.2014.12.051. Epub 2015 Mar 25. No abstract available.

PMID:
25819623
22.

Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes.

Wang J, Pettaway CA, Pagliaro LC.

Urology. 2015 May;85(5):1104-1110. doi: 10.1016/j.urology.2014.12.049. Epub 2015 Mar 25.

PMID:
25819619
23.

Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.

Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA.

Urol Oncol. 2015 Apr;33(4):166.e21-9. doi: 10.1016/j.urolonc.2014.11.021. Epub 2015 Feb 17.

24.

Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.

Reilley MJ, Pagliaro LC.

Curr Oncol Rep. 2015 Feb;17(2):2. doi: 10.1007/s11912-014-0430-0. Review.

PMID:
25645112
25.

Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy.

Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA.

BJU Int. 2016 Jan;117(1):118-25. doi: 10.1111/bju.12946. Epub 2015 Jun 3.

26.

Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM.

Cancer. 2015 Jan 1;121(1):69-76. doi: 10.1002/cncr.28971. Epub 2014 Aug 22.

27.

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.

Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC.

J Hematol Oncol. 2014 Aug 1;7:52. doi: 10.1186/s13045-014-0052-x.

28.

Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva.

Onaiwu CO, Ramirez PT, Kamat A, Pagliaro LC, Euscher EE, Schmeler KM.

Gynecol Oncol Case Rep. 2014 Apr 12;8:27-9. doi: 10.1016/j.gynor.2014.03.004. eCollection 2014 Apr. No abstract available.

29.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.

30.

Management of advanced primary urethral carcinomas.

Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C.

BJU Int. 2014 Jul;114(1):25-31. doi: 10.1111/bju.12630. Epub 2014 May 22. Review.

31.

Implications for human papillomavirus in penile cancer.

Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, Spiess PE.

Urol Oncol. 2014 Jan;32(1):53.e1-8. doi: 10.1016/j.urolonc.2013.08.010. Epub 2013 Nov 13. Review.

PMID:
24239463
32.

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB.

Urology. 2014 Jan;83(1):159-65. doi: 10.1016/j.urology.2013.08.074. Epub 2013 Nov 12. Erratum in: Urology. 2014 Jun;83(6):1446.

PMID:
24238569
33.

Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis.

Carthon BC, Ng CS, Pettaway CA, Pagliaro LC.

BJU Int. 2014 Jun;113(6):871-7. doi: 10.1111/bju.12450.

34.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.

Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM.

Eur J Cancer. 2013 Oct;49(15):3169-75. doi: 10.1016/j.ejca.2013.06.003. Epub 2013 Jun 26.

35.

Current concepts in penile cancer.

Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE.

J Natl Compr Canc Netw. 2013 May 1;11(5):617-24. Review.

PMID:
23667210
36.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ.

Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

37.

Bladder cancer.

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75.

PMID:
23584347
38.

Penile cancer: current therapy and future directions.

Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G.

Ann Oncol. 2013 May;24(5):1179-89. doi: 10.1093/annonc/mds635. Epub 2013 Jan 4. Review.

39.

Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.

Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM.

Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.

40.

Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists.

Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC.

Urol Oncol. 2013 Oct;31(7):1171-7. doi: 10.1016/j.urolonc.2012.01.011. Epub 2012 Apr 24.

41.

Malignant small round blue cell tumor of the kidney without EWSR1 rearrangement: report of a case and review of the literature.

Osai WE, Demicco EG, Pagliaro LC.

Clin Genitourin Cancer. 2012 Mar;10(1):63-5. doi: 10.1016/j.clgc.2011.11.001. Epub 2011 Dec 6. Review. No abstract available.

PMID:
22153153
42.

Systemic therapy for sarcomatoid renal cell carcinoma.

Pagliaro LC, Tannir N, Sircar K, Jonasch E.

Expert Rev Anticancer Ther. 2011 Jun;11(6):913-20. doi: 10.1586/era.11.39. Review.

PMID:
21707288
43.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29.

44.

Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC.

J Clin Oncol. 2011 Jun 20;29(18):2574-81. doi: 10.1200/JCO.2010.33.2999. Epub 2011 May 23.

45.

Penoscrotal extramammary Paget's disease: the University of Texas M. D. Anderson Cancer Center contemporary experience.

Hegarty PK, Suh J, Fisher MB, Taylor J, Nguyen TH, Ivan D, Prieto VG, Pagliaro LC, Pettaway CA.

J Urol. 2011 Jul;186(1):97-102. doi: 10.1016/j.juro.2011.02.2685. Epub 2011 May 14.

PMID:
21571343
46.

Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.

Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM.

BJU Int. 2011 Mar;107(5):741-747. doi: 10.1111/j.1464-410X.2010.09626.x. Epub 2010 Sep 21.

47.

Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature.

Watkins JL, Atkinson BJ, Pagliaro LC.

Ann Pharmacother. 2011 Feb;45(2):e9. doi: 10.1345/aph.1P433.

PMID:
21304039
48.

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM.

Ann Oncol. 2011 May;22(5):1048-53. doi: 10.1093/annonc/mdq563. Epub 2010 Nov 29.

49.

Long-term management of patients with metastatic renal cell carcinoma on targeted agents.

Jonasch E, Pagliaro LC, Tannir NM.

Expert Rev Anticancer Ther. 2010 Dec;10(12):1883-9. doi: 10.1586/era.10.195.

50.

Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience.

Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC.

Urol Oncol. 2012 Nov-Dec;30(6):879-85. doi: 10.1016/j.urolonc.2010.08.005. Epub 2010 Oct 8.

Supplemental Content

Loading ...
Support Center